Treatment With Tamoxifen in Cryptococcal Meningitis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

July 17, 2018

Study Completion Date

July 17, 2018

Conditions
Meningitis StreptococcalHivMeningitisMeningoencephalitis
Interventions
DRUG

Tamoxifen

Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.

DRUG

Amphotericin B

Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.

DRUG

Fluconazole

Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.

Trial Locations (3)

Unknown

Cho Ray Hospital, Ho Chi Minh City

Hospital for Tropical Diseases, Ho Chi Minh City

Oxford University Clinical Research Unit, Ho Chi Minh City

All Listed Sponsors
collaborator

Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

OTHER

collaborator

Cho Ray Hospital

OTHER

collaborator

University of Liverpool

OTHER

collaborator

University of Rochester

OTHER

collaborator

Liverpool School of Tropical Medicine

OTHER

lead

Oxford University Clinical Research Unit, Vietnam

OTHER

NCT03112031 - Treatment With Tamoxifen in Cryptococcal Meningitis | Biotech Hunter | Biotech Hunter